Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside

Journal of Pharmaceutical Sciences

Volumn 97, Issue 3, 2008, Pages 1213-1223

  Thomas, Chandan ^a   Rawat, Amit ^a   Bai, Shuhua ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Bronchoalveolar lavage; Hepatitis B surface antigen; Pulmonary delivery; Recombinant hepatitis B vaccine

Indexed keywords

ALKALINE PHOSPHATASE; DODECYL SULFATE SODIUM; HEPATITIS B SURFACE ANTIGEN; LACTATE DEHYDROGENASE; RECOMBINANT HEPATITIS B VACCINE; TETRADECYL BETA MALTOSIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DRUG DERIVATIVE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; MALTOSE; TETRADECYL MALTOSIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; IMMUNE RESPONSE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG INJURY; LUNG LAVAGE; MALE; NONHUMAN; RAT; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; FEASIBILITY STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; MALE; MALTOSE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42949133531     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21069     Document Type: Article

References (36)

1. Levine MM. 2003. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9:99-103.
2. Lai CL, Ratziu V, Yuen MF, Poynard T. 2003. Viral hepatitis B. Lancet 362:2089-2094.
3. Zuckerman JN, Zuckerman AJ. 2000. Current topics in hepatitis B. J Infect 41:130-136.
4. Cui Z, Mumper RJ. 2002. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 54:1195-1203.
5. Mestecky J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 7:265-276.
6. Ogra PL, Faden H, Welliver RC. 2001. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14:430-445.
7. Gander B. 2005. Trends in particulate antigen and DNA delivery systems for vaccines. Adv Drug Deliv Rev 57:321-323.
8. Poirriez J. 2002. Some questions to be raised about the hepatitis B vaccine. Vaccine 20:1696-1698.
9. Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. 2003. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 81:52-58.
10. Ilium L, Davis SS. 2001. Nasal vaccination: A noninvasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51:1-3.
11. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 57:411-430.
12. Bivas-Benita M, Ottenhoff TH, Junginger HE, Borchard G. 2005. Pulmonary DNA vaccination: Concepts, possibilities and perspectives. J Control Release 107:1-29.
13. de Haan A, Renegar KB, Small PA Jr, Wilschut J. 1995. Induction of a secretory IgA response in the murine female urogenital tract by immunization of the lungs with liposome-supplemented viral subunit antigen. Vaccine 13:613-616.
14. Hussain A, Yang T, Zaghloul AA, Ahsan F. 2003. Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin. Pharm Res 20:1551-1557.
15. Bivas-Benita M, van Meijgaarden KE, Franken KL, Junginger HE, Borchard G, Ottenhoff TH, Geluk A. 2004. Pulmonary delivery of chitosan-DNA nano-particles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201- restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22:1609-1615.
16. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. 2006. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 24:45-56.
17. Holt PG, Oliver J, Bilyk N, McMenamin C, McMenamin PG, Kraal G, Thepen T. 1993. Down-regulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 177:397-407.
18. Stumbles PA, Upham JW, Holt PG. 2003. Airway dendritic cells: Co-ordinators of immunological homeostasis and immunity in the respiratory tract. APMIS 111:741-755.
19. Yang T, Mustafa F, Bai S, Ahsan F. 2004. Pulmonary delivery of low molecular weight heparins. Pharm Res 21:2009-2016.
20. Hussain A, Majumder QH, Ahsan F. 2006. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res 23:138-147.
21. Hussain A, Ahsan F. 2005. State of insulin self-association does not affect its absorption from the pulmonary route. Eur J Pharm Sci 25:289-298.
22. Elias F, Flo J, Rodriguez JM, De Nichilo A, Lopez RA, Zorzopulos J, Nagle C, Lahoz M, Montaner A. 2005. PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant hepatitis B vaccine that enhances the Th1 response. Vaccine 23:3597-3603.
23. Bai S, Thomas C, Ahsan F. 2007. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low molecular weight heparin. J Pharm Sci Feb 7; DOI 10.1002/jps.20849.
24. Argentini C, Giuseppetti R, D'Ugo E, La Sorsa V, Tritarelli E, Orobello S, Canitano A, Gluck R, Rapicetta M. 2005. A pre-S/S CHO-derived hepatitis B virus vaccine protects woodchucks from WHV productive infection. Vaccine 23:3649-3656.
25. Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, Gupta PN, Rawat A, Dubey P. 2005. Nonionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 296:80-86.
26. Lombry C, Marteleur A, Arras M, Lison D, Louahed J, Renauld JC, Preat V, Vanbever R. 2004. Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice. Pharm Res 21:127-135.
27. Aguilar JC, Lobaina Y, Muzio V, Garcia D, Penton E, Iglesias E, Pichardo D, Urquiza D, Rodriguez D, Silva D, Petrovsky N, Guillen G. 2004. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 82: 539-546.
28. Maa YF, Shu C, Ameri M, Zuleger C, Che J, Osorio JE, Payne LG, Chen D. 2003. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm Res 20:969-977.
29. Xia W, Pinto CE, Kradin RL. 1995. The antigen-presenting activities of Ia+ dendritic cells shift dynamically from lung to lymph node after an airway challenge with soluble antigen. J Exp Med 181:1275-1283.
30. Raghuvanshi RS, Ganga S, Mishra A, Mehta S. 1996. Stabilisation of tetanus toxoid against dichloromethane. Proc Int Symp Control Release Bioct Mater 23:859-860.
31. Tamber H, Johansen P, Merkle HP, Gander B. 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-376.
32. Janeway CA, Travers P, Walport M, Capra JD. 1999. The induction, measurement and manipulation of the immune response. Immunobiology: The immune system in health and disease. New York: Taylor and Francis. pp 37-76.
33. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, Nagai T. 2006. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release 112:35-42.
34. Xu H, Verbeken E, Vanhooren HM, Nemery B, Hoet PH. 2004. Pulmonary toxicity of polyvinyl chloride particles after a single intratracheal instillation in rats. Time course and comparison with silica. Toxicol Appl Pharmacol 194:111-121.
35. Toews GB. 2001. Cytokines and the lung. Eur Respir J 18:3s-17s.
36. Hickey AJ, Garcia-Contreras L. 2001. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: Relevance to humans. Crit Rev Ther Drug Carrier Syst 18:387-431.